• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Inhaled Parkinson’s treatment improves motor function in Phase III

June 6, 2017 By Sarah Faulkner

Acorda TherapeuticsShares in Acorda Therapeutics (NSDQ:ACOR) jumped this morning after the company reported that its inhaled Parkinson’s drug significantly improved motor function in a Phase III trial.

The investigational drug is being studied as a therapy for people with Parkinson’s disease experiencing “off” periods, or a re-emergence of symptoms.

The Phase III Span-Pd trial enrolled 339 patients with Parkinson’s disease and found that 84 milligrams of CVT-301 improved motor function compared to placebo, measured at 30 minutes post-dose after 12 weeks.

The Ardsley, N.Y.-based company said the trial’s results were presented at the International Congress of Parkinson’s Disease and Movement Disorders in Vancouver, British Columbia.

The most commonly reported adverse events in the CVT-301 group were cough, upper respiratory tract infection, nausea, sputum discoloration and dyskinesia. Two of the 114 patients that were treated with CVT-301 withdrew from the study due to a cough.

Acorda also touted interim data from an ongoing long-term safety study. The primary objective of the 52-week study is to evaluate pulmonary function by measuring forced expiratory volume in 1 second and diffusing capacity of the lung for carbon monoxide.

There were no statistical differences in the mean changes of either measure from baseline until week 52 between the CVT-301 group and the control group.

Seventeen patients in this trial suffered fractures, but they were judged be unlikely or not related to CVT-301. Three of the 271 patients receiving CVT-301 had to stop participating due to a cough.

There was also 1 death in the trial, but the researchers determined it was not related to Acorda’s drug.

The trial included several exploratory efficacy measurements that were only assessed in the CVT-301 branch. At 52 weeks, 85% of patients maintained an “on” state 60 minutes post-dose and 73% of patients reported motor improvements.

Over the course of the study, the average patient used 2.3 doses of CVT-301 each day.

The company said it plans to file a new drug application for its inhaled Parkinson’s drug with the FDA by the end of the 2nd quarter of this year, as well as a marketing authorization application with the EMA by the end of 2017.

ACOR shares were trading at $16.60 apiece in early-morning activity, up 8.5%.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Acorda Therapeutics

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS